Skip to main content
. 2017 Jan 30;7:41615. doi: 10.1038/srep41615

Figure 2. Synergistic effect of CG200745 combined with gemcitabine/erlotinib in pancreatic cancer cell lines (BxPC3).

Figure 2

The doses of erlotinib and CG200745 were equivalent to IC 20~30. (A) The growth of pancreatic cells was analyzed via an MTT assay after treatment with various concentrations of gemcitabine over a time-course (0–72 h). The anti-proliferative effect of CG200745 with gemcitabine/erlotinib is more enhanced than the effect of gemcitabine/erlotinib without CG200745 in pancreatic cancer cells. (B) Western Blot analysis to investigate the pancreatic cancer cell apoptosis and analyze the molecular pathway related to CG200754. CG200745 combined with gemcitabine/erlotinib induces apoptosis through caspase-3 activation. (C) Immunofluorescent staining of cleaved caspase-3 expressing cells. Fluorescence signals specific to cleaved caspase-3 antibodies were visualized as green, and DAPI (blue) was used to indicate nuclei. * or **Indicates significant differences compared with the control (p < 0.05 or p < 0.01). G, gemcitabine; CG, CG200745; E, erlotinib.